Regional Dermatology Partners with Epiphany Dermatology
Regional Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Missouri through its partnership with…
Newron Pharmaceuticals Obtains Up to EUR 38 Million to Propel Late-Stage Evenamide Program
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program Newron Pharmaceuticals S.p.A. a biopharmaceutical company focused on the development of novel therapies for patients with diseases…
VB Spine Moves to Secure Exclusive Rights to Augmedics’ Spine Technology Platform
VB Spine Announces Intent to Acquire Exclusive Rights to Augmedics’ Spine Platform VB Spine LLC the largest privately held spine company, today announced it has entered into a definitive agreement to acquire…
DeciBio Consulting Unveils Data Report on Oncology Genomics Trends Across Europe
Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and…
Worldwide Clinical Trials Finalizes Acquisition of Catalyst Clinical Research
Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional…
ECCO Data Highlight Remsima™ SC’s Ability to Restore and Sustain Disease Control After Treatment Break
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal…
Genentech Highlights Breakthrough Phase III Results for Gazyva in Autoimmune Kidney Disease
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease Genentech, a member of the Roche Group announced today that…
Quantum-Si Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that…
Promega Presents Breakthrough Cellular Target Engagement Platform at SLAS 2026
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 2026 Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap…
Arintra Slashes Coding Expenses and Achieves Strong Retention with 8X Revenue Expansion
Arintra Cuts Coding Costs by Nearly One-Third for Customers, Driving Industry-Leading Retention and 8X Revenue Growth Arintra, the leading GenAI-native autonomous medical coding platform for healthcare organizations, today announced it…
Corazon, Columbia HeartSource Introduce First-of-Its-Kind Open-Heart Surgery Accreditation
Corazon and Columbia HeartSource Announce Partnership Offering First-of-its-Kind Open-Heart Surgery Accreditation Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a…
RxERP, p-Chip Corporation Partner on Licensing Agreement to Support DSCSA Compliance
RxERP and p‑Chip Corporation Announce Licensing Agreement to Enable Embedded Unit‑Level Digital Identity for DSCSA Compliance and End‑to‑End Pharmaceutical Traceability RxERP, a cloud-hosted, pharmaceutical-first ERP platform, and p‑Chip Corporation (“p‑Chip”),…